Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine.
Amic. Fedor F; Drmic. Domagoj D; Bilic. Zdenko Z; Krezic. Ivan I; Zizek. Helena H; Peklic. Marina M; Klicek. Robert R; Pajtak. Alen A; Amic. Enio E; Vidovic. Tinka T; Rakic. Mislav M; Milkovic Perisa. Marija M; Horvat Pavlov. Katarina K; Kokot. Antonio A; Tvrdeic. Ante A; Boban Blagaic. Alenka A; Zovak. Mario M; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 dramatically reduced duodenal lesions and congestion after a major vein was tied off.
- The peptide promoted rapid formation of alternative blood‑vessel pathways, increasing vessel branching by over 60%.
- BPC‑157 normalized nitric‑oxide and malondialdehyde (oxidative stress) levels in the gut, even when NO‑modulating drugs were present.
Practical Outcomes
- For biohackers focused on gut and vascular health, oral BPC‑157 (around 10 µg/kg) may help protect the intestine from injury and support collateral blood flow. The study suggests the peptide works independently of the nitric‑oxide system, so it could be combined with other NO‑modulating supplements without losing effect. However, human data are still needed, so start with low doses and monitor gut tolerance.
Summary
In rats where a major vein feeding the duodenum was blocked, giving the peptide BPC‑157 (either directly at the blockage site or by swallowing it) quickly reduced gut damage, helped new blood‑vessel routes form, and restored normal nitric‑oxide and oxidative‑stress levels. The benefits held even when other drugs that affect nitric‑oxide were added.
Abstract
To investigate whether duodenal lesions induced by major venous occlusions can be attenuated by BPC 157 regardless nitric oxide (NO) system involvement. Male Wistar rats underwent superior anterior pancreaticoduodenal vein (SAPDV)-ligation and were treated with a bath at the ligated SAPDV site (BPC 157 10 μg, 10 ng/kg per 1 mL bath/rat; L-NAME 5 mg/kg per 1 mL bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, alone and/or together; or BPC 157 10 μg/kg instilled into the rat stomach, at 1 min ligation-time). We recorded the vessel presentation (filled/appearance or emptied/disappearance) between the 5 arcade vessels arising from the SAPDV on the ventral duodenum side, the inferior anterior pancreaticoduodenal vein (IAPDV) and superior mesenteric vein (SMV) as bypassing vascular pathway to document the duodenal lesions presentation; increased NO- and oxidative stress [malondialdehyde (MDA)]-levels in duodenum. Unlike the severe course in the SAPDV-ligated controls, after BPC 157 application, the rats exhibited strong attenuation of the mucosal lesions and serosal congestion, improved vessel presentation, increased interconnections, increased branching by more than 60% from the initial value, the IAPDV and SMV were not congested. Interestingly, after 5 min and 30 min of L-NAME and L-arginine treatment alone, decreased mucosal and serosal duodenal lesions were observed; their effect was worsened at 24 h, and no effect on the collateral vessels and branching was seen. Together, L-NAME+L-arginine antagonized each other's response, and thus, there was an NO-related effect. With BPC 157, all SAPDV-ligated rats receiving L-NAME and/or L-arginine appeared similar to the rats treated with BPC 157 alone. Also, BPC 157 in SAPDV-ligated rats normalized levels of NO and MDA, two oxidative stress markers, in duodenal tissues. BPC 157, rapidly bypassing occlusion, rescued the original duodenal flow through IAPDV to SMV flow, an effect related to the NO system and reduction of free radical formation.
Study Information
pubmed
2018
2018-12-21T00:00:00.000Z
10.3748/wjg.v24.i47.5366
38
51